ABN is working under a Saltonstall-Kennedy grant to develop a novel platform technology for oral vaccines to combat fish diseases. The company's initial focus is on IPNV and ISA, diseases which cause considerable losses in the global salmon industry each year.

ABN is developing "ghost"
viruses that are effective
without being infective.